S.R. One Limited
Investment Details
Investor Type
Corporate VC
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United States, United Kingdom
Industries Focus
- Healthcare
- Food and Beverage
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Consumer Health
- Agricultural Biotechnology
- Medical Equipment
- Industrial Biotechnology
- Veterinary Medicine
- Cosmetics
- Environmental Biotechnology
Investor Details Founded: 1985
S.R. One Limited is the corporate venture capital arm of GlaxoSmithKline (GSK), focusing on investments in emerging life science companies that are pursuing innovative science with the potential to significantly impact medical care. With a team of investment professionals located in the United States and the United Kingdom, S.R. One has invested over $1 billion in more than 170 companies since its inception in 1985. The firm's portfolio includes both private and public companies across various stages of development.
The firm's investment strategy emphasizes active involvement in portfolio companies, collaborating with management teams and fellow venture investors to create significant value. S.R. One's expanded remit also focuses on maximizing the value of GSK's technological innovation to establish new businesses and revenue opportunities across a range of industries. This approach reflects a commitment to fostering innovation and driving growth within the life sciences sector.
Celebrating its 30th anniversary in 2015, S.R. One continues to be a prominent player in the venture capital landscape, leveraging its deep industry expertise and global network to support the growth and success of its portfolio companies. The firm's strategic focus on life sciences and its active investment approach have contributed to its reputation as a leading corporate venture capital firm in the biotechnology sector.
Requirements
- Innovative life science companies with significant impact potential
- Strong management teams
- Global market reach
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Thermo Fisher Scientific
- Alnylam Pharmaceuticals
- Immunocore
- Vir Biotechnology
- Editas Medicine
- Mersana Therapeutics
- Kymab
- Autolus
- CureVac
- Cell Medica
- Celyad
- CureMetrix
Mentioned In
-
$24.95
-
$14.95
-
$19.95
-
$24.95
-
$99.00
Claim this Investor
Are you an official representative of S.R. One Limited?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim